Quick Answer
Cytosorbents Corp reported Stockholders Equity of $5.90 million for fiscal year 2025.
Cytosorbents Corp Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $5.90M | -46.9% |
| 2024 | $11.11M | -15.5% |
| 2024 | $13.14M | -24.6% |
| 2024 | $17.43M | -11.2% |
| 2024 | $19.63M | -16.4% |
| 2023 | $23.48M | +24.8% |
| 2023 | $18.81M | -23.1% |
| 2023 | $24.46M | -18.3% |
| 2023 | $29.94M | -15.4% |
| 2022 | $35.37M | -43.5% |
| 2021 | $62.58M | -21.0% |
| 2020 | $79.22M | +2217.6% |
| 2019 | $3.42M | -79.8% |
| 2018 | $16.93M | +65.0% |
| 2017 | $10.26M | +667.3% |
| 2016 | $1.34M | -86.4% |
| 2015 | $9.85M | +41.8% |
| 2014 | $6.94M | +148.7% |
| 2013 | -$14.27M | -22.7% |
| 2012 | -$11.63M | -15.2% |
| 2011 | -$10.09M | -25.1% |
| 2010 | -$8.07M | -40.5% |
| 2009 | -$5.74M | -71.6% |
| 2008 | -$3.35M | -3107.9% |
| 2007 | -$104.3K | -104.4% |
| 2006 | $2.36M | +124.2% |
| 2005 | -$9.76M | -40.1% |
| 2004 | -$6.97M | -78.3% |
| 2003 | -$3.91M | +10.7% |
| 2002 | -$4.37M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $9.02M | -32.6% | -22.1% |
| June 30, 2025 | $11.59M | -33.5% | -20.3% |
| March 31, 2025 | $14.54M | -25.9% | +30.9% |
| December 31, 2024 | $11.11M | -52.7% | -17.0% |
| September 30, 2024 | $13.38M | -27.7% | -23.2% |
| June 30, 2024 | $17.43M | -27.7% | -11.2% |
| March 31, 2024 | $19.63M | -32.2% | -16.4% |
| December 31, 2023 | $23.48M | -33.6% | +26.8% |
- Cytosorbents Corp showed a decrease of -46.9% in Stockholders Equity compared to the prior fiscal year.
- Over the 2002–2025 period, Cytosorbents Corp’s stockholders equity has grown by 234.9% (from -$4.37 million to $5.90 million).
- The most recent figure is from Cytosorbents Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: